Meeting
2023 ASCO Annual Meeting
Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions.
Authors
Monica F Chen
Memorial Sloan Kettering Cancer Center, New York, NY
Monica F Chen , Soo-Ryum Yang , Jessica Tao , Antoine Desilets , Ezra Rosen , Yixuan Gong , Kerry A. Mullaney , Mark G. Kris , Maria E. Arcila , Mark Donoghue , Romel Somwar , Marc Ladanyi , Neal Rosen , Rona Yaeger , Alexander E. Drilon , Michael Offin , Yonina R. Murciano-Goroff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3146)
DOI
10.1200/JCO.2023.41.16_suppl.3146
Abstract #
3146
Poster Bd #
344
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Comprehensive Genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
First Author: Saad A. Khan
Poster
2016 ASCO Annual Meeting
Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials.
First Author: Vlad Sandulache
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2023 ASCO Annual Meeting
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
First Author: Oriol Mirallas